• Users Online: 403
  • Print this page
  • Email this page

 
Table of Contents
ORIGINAL ARTICLE
Year : 2020  |  Volume : 6  |  Issue : 3  |  Page : 353-361

The antitumor activity and mechanism of MCL3 in G422 glioblastoma


1 Department of Pharmacology, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Date of Submission01-Apr-2020
Date of Acceptance01-Jun-2020
Date of Web Publication05-Sep-2020

Correspondence Address:
Prof. Xian-Dao Pan
Institute of Materia Medica, Chinese Academy of Medical Sciencesand Peking Union Medical College, 1 Xian Nong Tan Street, Beijing
China
Prof. Yan Li
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nong Tan Street, Beijing
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/wjtcm.wjtcm_46_20

Rights and Permissions
  Abstract 


Objective: Parthenolide (PTL) induces anti-tumor effects via the nuclear factor kappa B (NF-κB) signaling pathway. MCL3, a PTL derivative, is a sesquiterpene lactone synthesized by the rearrangement and subsequent oxidation of PTL. The aim of this study was to elucidate the antitumor activity and mechanism of action of MCL3 in glioblastoma (GBM). Materials and Methods: The effects of MCL3 on G422 cell proliferation, apoptosis, invasion, and angiogenesis in vitro were measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, flow cytometry, the cell invasion, and tube formation assays. The subcutaneously transplanted G422 xenograft model was used to detect the effect of MCL3 on tumor growth in vivo. Pathological changes were analyzed by immunohistochemical staining. The effects of MCL3 on NF-κB and Stat3 transcriptional activities were examined using a dual-luciferase reporter assay. Protein levels related to the NF-κB/ interleukin (IL)-6/Stat3 signaling pathway were determined using western blot analysis. Results: MCL3 inhibited GBM cell proliferation, invasion, and angiogenesis in a concentration-dependent manner. Moreover, MCL3 decreased the transcriptional activities of NF-κB and Stat3. MCL3 suppressed tumor growth in the subcutaneously transplanted G422 xenograft model, while the inhibition rate was 79% in tumor weight at 40.0 mg/kg. MCL3 blocked the NF-κB/IL-6/Stat3 signaling pathway in G422 cells and tumor tissues, resulting in the downregulation of Stat3 target genes related to apoptosis, invasion, etc., Conclusion: The results show that MCL3 might inhibit G422 GBM growth partly due to the inhibition of the NF-κB/IL-6/Stat3 signaling pathway.

Keywords: Glioblastoma, MCL3, nuclear factor kappa B/interleukin-6/Stat3, parthenolide derivative


How to cite this article:
Du QQ, Tang M, Huang LL, Zhao R, Yan C, Li Y, Pan XD. The antitumor activity and mechanism of MCL3 in G422 glioblastoma. World J Tradit Chin Med 2020;6:353-61

How to cite this URL:
Du QQ, Tang M, Huang LL, Zhao R, Yan C, Li Y, Pan XD. The antitumor activity and mechanism of MCL3 in G422 glioblastoma. World J Tradit Chin Med [serial online] 2020 [cited 2020 Sep 24];6:353-61. Available from: http://www.wjtcm.net/text.asp?2020/6/3/353/294390




  Introduction Top


Glioblastoma (GBM) is the most frequent and aggressive primary malignant brain tumor related to poor prognosis and limited treatment.[1] Adjuvant radiotherapy combined with chemotherapy is typically prescribed for patients, although some patients undergoing this treatment also had increased tumor size and side effects. Therefore, it is important to improve the treatment options for patients with GBM.[2],[3]

Traditional Chinese Medicine (TCM) has formed its own unique system of theories, diagnostics and therapies in China, and studies have shown that TCM could play an important role in cancer prevention and treatment.[4] Many countries, including the United States of America, have attempted to undertake TCM-related research projects.[5] TCM, in combination with chemotherapy, could suppress tumor growth, increase the sensitivity of chemotherapeutic drugs, while decreasing their side effects.[4],[6] In the last few decades, TCM has been used widely for cancer therapy around the world.

Sesquiterpene lactones including parthenolide [PTL, [Figure 1] were extracted from the feverfew plant (Tanacetum parthenium), which were primarily used for the treatment of skin infection, arthritis, and migraines.[7] In recent studies, PTL was observed to inhibit proliferation of cancer cells, particularly prostate, breast, gastric, renal cell carcinoma, lung, and colon cancers.[8],[9],[10],[11],[12] Moreover, there is evidence that PTL exhibits anti-tumor activity, including against GBM, by suppressing the activation of nuclear factor kappa B (NF-κB) mediated by IκB, resulting in inhibition of interleukin (IL)-6-induced Stat3 activation.[11],[13],[14],[15],[16] This mechanism may be the Michael addition reaction of a thiol group on Cys38 of p65/NF-κB with PTL.[10],[17] Since NF-κB was associated with tumor invasion, metastasis, and drug resistance, suppression of NF-κB could improve the sensitivity of cancer cells to anti-cancer drugs.
Figure 1: Chemical structures of parthenolide, MCL3

Click here to view


MCL3 [Patent: 201711285215.2, [Figure 1] was synthesized using a three-step reaction from PTL.[18] In this study, the antitumor activity and mechanism of MCL3 against GBM were investigatedin vitro and in vivo. We found that MCL3 induced antitumor activity in G422 GBM by targeting the NF-κB/IL-6/Stat3 signaling pathway.


  Materials and Methods Top


Cell lines and culture

NCI-H1650 and NCI-H460 human lung cancer cell lines, MCF7 and MDA-MB-231 human breast cancer cell lines, BxPc3 human pancreatic cancer cell line, U-87 MG, U251, and Hs683 human brain tumor cells, HCT-8 human colon cancer cell lines, and BGC-823 human gastric cancer cell line, were obtained from the Cell Center of CAMS and PUMC in Beijing. MGC-803 and HGC27 human gastric cancer cell lines, HCT15 human colon cancer cell lines, Mia-PaCa2 human pancreatic cancer cell lines were received from Tsinghua University in Beijing. Caki-1 and ACHN human renal cell carcinoma cell lines were received from DUKE-NUS Medical School Singapore. Capan2 human pancreatic cancer cell line was obtained from Shanghai Xiangf Bio in Shanghai. G422-GFP mouse brain tumor cell line was obtained from Guangzhou Jennio Biotechin Guangzhou. U-87 MG cells were incubated in Minimum Essential Media (MEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) added to 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), 100 IU/mL penicillin, and 100 μg/mL streptomycin. HGC27, HCT15, HCT-8, NCI-H1650, and NCI-H460 were cultured in 1640 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) added to 10% FBS, 100 IU/mL penicillin, and 100 μg/mL streptomycin. Other cells were grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc.,) added to 10% FBS, 100 IU/mL penicillin, and 100 μg/mL streptomycin. Cells were cultured in a humidified atmosphere of 5% CO2 at 37°C.

Drugs and compounds

MCL3 was synthetized, while Pan and temozolomide (TMZ) were purchased from Shanghai Biolang Bio-tech Co., Ltd in Shanghai. For thein vitro experiments, MCL3 was made in solution dimethyl sulfoxide (DMSO) solution and maintained at 4°C. DMSO was used as the vehicle controlin vitro experiments at a concentration of 0.1%. Considering the experiments in vivo, MCL3 and TMZ were dissolved in a solution of 25% PEG400.

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay

Cells (100 μL) were added to 96-well plates and incubated for 24 h. Different concentrations of MCL3 were then added to per well for 100 μL. After 96 h, 50 μL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (2.0 mg/mL) was added and incubated for a further 4 h. The solution was removed, and 150 μL DMSO was added. The optical density was measured at 570 nm by an ELISA reader (WD-2102A, China). All experiments were performed in triplicate.

Cell apoptosis assay

G422 cells were cultured for 24 h, and different concentrations of MCL3 (3.33 μmol/L, 10.00 μmol/L, 30.00 μmol/L) were added to per well for 100 μL. Following incubation for 72 h, cells were harvested, and washed with cold PBS. Subsequent to suspension in binding buffer, cells were stained with 100 μL PI. The cell samples were analyzed using ACCURI C6 flow cytometer.

Cell invasion assay

An invasion assay was achieved using transwell inserts containing polycarbonate filters with 8.0 μm pores. Matrigel (10 μL, 1.0 mg/mL) was supplied using the upper chamber. The cells (7 × 105 cells/well) were suspended in 200 μL 0.1% BSA with different concentrations of MCL3 (1.11 μmol/L, 3.33 μmol/L, 10.00 μmol/L), and seeded into the upper chamber; 600 μL normal medium (10% FBS, 100 IU/mL penicillin, and 100 μg/mL streptomycin) was placed in the lower chambers. The control group did not add MCL3. Following 24 h incubation at 37°C in an atmosphere of 5% CO2, the cells on the upper cover of the membrane were mechanically removed, while the invading cells on the lower cover were fixed with methanol, and stained with hematoxylin and eosin (H and E) dye. The number of invasive cells in four random fields per membrane was counted at ×200 magnification (Olympus IX70). The experiment was performed in triplicate.

Tube formation assay

A total of 50,000 EA. hy926 cells, which were suspended in 100 μL DMEMwith different concentrations of MCL3 (3.33 μmol/L, 10.00 μmol/L, 30.00 μmol/L), were added into a 96-well plate precoated with Matrigel. After maintenance at 37°C for 5 h, EA. hy926 cells were examined for capillary-like tube formation and photographed under a microscope (×100 magnification, Olympus IX70). All experiments were performed in triplicate.

G422 glioblastoma xenograft model

Procedures for the animal study were performed with the approval of the Animal Care and Use Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College. Four to 6-week-old male mice (National Institutes for Food and Drug Control) were used. G422 GBM tumors implanted in the axillary of these mice were removed and homogenized. Tumor cells were diluted with aseptic saline in a ratio of 1:3 to form a tumor solution. Test mice were then injected with 0.2 mL tumor solution in the left flank. The tumor-bearing mice were divided into five groups, each containing six mice. All groups were fed with drugs from the next day. The control group was orally fed with 25% PEG400; while the other groups were administered an oral dose of 30.0 mg/kg TMZ for 5 days, followed by 10.0 mg/kg, 20.0 mg/kg, and 40.0 mg/kg MCL3 for 2 weeks. Mice were mercy killed at the final period of the experiment. Tumors were excised, weighed, and photographed. The inhibition rate was calculated based on the size of the tumor and growth period. A sample of the tumor was fixed with 4% paraffin for immunohistochemical (IHC) staining, while the other tissues were maintained at −80°C to be used in western blot analysis.[19]

A dual luciferase assay

The luciferase reporter plasmid, including the NF-κB-binding site (pGMNF-κB-Lu), and the TK-Renilla luciferase plasmid (pGMR-TK) were obtained from Genomeditech Shanghai Co. Ltd in Shanghai. G422-GFP cells in 96-well plates were co-transfected with pGMR-TK and pGMGLI1-Lu as per the Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.,) standard protocol. After transfection for 6 h, cells were supplemented with various concentrations of MCL3, and incubated for a further 48 h. Luciferase assays were measured by a dual luciferase reporter assay system (Promega Corporation; cat. no., E1960), as per the product's protocol. Luciferase values were normalized to Renilla values. The transcription activity of Stat3 was detected by the Eastinno Biotechnology. Co. Ltd in Zhejiang by the dual luciferase assay.

Immunohistochemistry assay

Immunohistochemistry staining for proliferating cell nuclear antigen (PCNA) (1:5000 dilutions) and CD34 (1:5000 dilutions) was performed as previously described.[20],[21],[22] Brown stained cells were defined PCNA-positive and CD34-positive cells. The expression of PCNA was quantified using the proliferation index, while CD34 quantified using the microvessel density (MVD) according to the Weidner's method.[23] MVD is used to analyze the level of angiogenesis. MVD was evaluated by Weidner's method.[24]

Western blot assay

Tissues from three randomly selected tumors from G422 xenograft mice of the control, and 20.0 mg/kg and 40.0 mg/kg MCL3 groups were lysed. G422 cells were incubated with MCL3 for 72 h. The total protein in these cells was refined by the radioimmunoprecipitation assay buffer (RIPA, R0020; Beijing Solarbio Science and Technology Co., Ltd) and phenylmethanesulfonyl fluoride (PMSF; P0100; Beijing Solarbio Science and Technology Co., Ltd). Nuclear protein was obtained using the Nuclear and Cytoplasmic Extraction Kit (CW0199S; CWBIO). The total protein quantity was evaluated using the BCA Protein Assay Kit (PC0020; Beijing Solarbio Science and Technology Co., Ltd). Total proteins (35 μg) and nuclear proteins (25 μg) were maintained separately in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transported to the PVDF membrane. The membranes were blocked using a solution of TBS consisting of 1% Tween® 20 and 5% skimmed dry milk, and maintained with the specific primary antibodies (dilution, 1:1,000; Cell Signaling Technology, Inc., Shanghai, China; Abcam Trading, Shanghai, Ltd) overnight at 4°C. The samples were detected using the secondary antibody of a horseradish peroxidase-labeled goat (dilution, 1:5,000; cat. no., sc-2004; Santa Cruz Biotechnology, Inc.,) for 1 h at 25°C an enhanced chemiluminescence western blot system (Applygen Technologies, Inc.,) was used for detection. β-actin and histone H3 were used as loading controls.

Statistical analysis

Data are expressed as the mean ± standard deviation. Two-tailed independent Student's t-test (Microsoft Excel, 2010) was performed and P < 0.05 was confirmed to indicate a statistical difference.


  Results Top


MCL3 inhibited the cell proliferation

Anti-proliferation activity was examined in different cancer cell lines treated with MCL3 for 96 h using the MTT assay, with the IC50 values ranging between 6.44 and 23.40 μmol/L [Table 1]. The GBM cell lines were more sensitive to MCL3, including G422, U-87 MG, U251, and Hs683 cell lines. The IC50 values were 8.94 ± 1.33 μmol/L, 6.44 ± 1.80 μmol/L, 14.80 ± 9.30 μmol/L, and 18.90 ± 4.10 μmol/L, respectively [Figure 2].
Table 1: Summary of IC50 values for MCL3 on different cancer cell lines

Click here to view
Figure 2: IC50 values of U87MG, U251, Hs683 and G422 cell lines treated with MCL3

Click here to view


MCL3 induced G422 cell apoptosis

Apoptotic activity of MCL3 was investigated by flow cytometry. After G422 treated with MCL3 for 72 h, the G422 cell apoptotic rate increased in a dose-dependent manner. The apoptotic rates were 20.7 ± 1.4% (P < 0.05) and 29.7 ± 0.8% (P < 0.001) in the 10.00 μmol/L and 30.00 μmol/L groups, respectively. While the control group had a 16.2 ± 1.6% rate of apoptosis [Figure 3]. The result suggests that MCL3 could induce apoptosis in G422 cells.
Figure 3: The effect of MCL3 on G422 cell apoptosis. Each graph represents the mean, and the error bars represent standard deviation. *P < 0.05, ***P < 0.001 compared with control group

Click here to view


MCL3 suppressed G422 cell invasion

The transwell assay was used to determine the influence of MCL3 on G422 cell invasion ability. MCL3 decreased the number of transmembrane G422 in a concentration-dependent manner. The inhibition rates were 23.9% (P < 0.01) and 43.6% (P < 0.01) in the 3.33 μmol/L and 10.00 μmol/L MCL3 groups, respectively [Figure 4]. While MCL3 did not influence the cell proliferation at these concentrations for 24 h, according to results of the MTT assay. The data showed MCL3 inhibited the invasion of G422 cells in vitro.
Figure 4: The effect of MCL3 on G422 cells invasion ability. Each graph represents the mean, and the error bars represent standard deviation. **P < 0.01 compared with control group

Click here to view


MCL3 inhibited the tube formation of EA. hy926 cells

The influence of MCL3 on the formation of vessels was explored by a capillary-like tube formation assay. The growth of new microvessels was inhibited in EA. hy926 cells after the treatment of various concentrations of MCL3. The inhibition rates were 24.8% (P < 0.01), 81.7% (P < 0.0001), and 91.9% (P < 0.0001) in the 3.33 μmol/L, 10.00 μmol/L, and 30.00 μmol/L MCL3 groups, respectively [Figure 5]. These results indicated MCL3 had an inhibitory effect onin vitro tube formation.
Figure 5: The effect of MCL3 on tube formation. **P < 0.01, ***P < 0.001 compared with control group

Click here to view


MCL3 inhibited G422 tumor growth in vivo

The subcutaneously transplanted G422 xenograft model was used to determine the anti-tumor activity of MCL3 in vivo. The results indicate that MCL3 suppressed the tumor growth at a dose-dependent manner in a subcutaneously transplanted G422 xenograft mice model [Figure 6], and the inhibition rate was 79.0% (P < 0.001) in tumor weight at 40.0 mg/kg [Table 2].
Figure 6: The effect of MCL3 on the tumor growth in subcutaneously transplanted G422 xenograft model

Click here to view
Table 2: The effect of MCL3 on the tumor growth in subcutaneously transplanted G422 xenograft model

Click here to view


MCL3 suppressed the G422 tumor cell proliferation and angiogenesis in vivo

PCNA is the marker used to calculate cell proliferation rate. IHC staining showed that the lowest level of PCNA protein expression was detected in tumors treated with 40.0 mg/kg MCL3 compared to the control [Figure 7]a, while the inhibition rate was 36.3% (P < 0.001). The study used CD34 to evaluate the differences between MVD in the control and the 40.0 mg/kg MCL3 groups. Decreased tumor MVD was noted in the MCL3 group with an inhibition rate of 66.1% (P < 0.5), which contrasted with the control [Figure 7]b. The results showed that MCL3 suppressed tumor cell proliferation and angiogenesis in G422 xenograft model.
Figure 7: Detection of proliferating cell nuclear antigen and CD34 expression in G422 xenograft tumor tissues analyzed by immunohistochemical assay. (a) MCL3 lowered the proliferation index evaluated by proliferating cell nuclear antigen staining (×20), ***P < 0.001 compared with control group. (b) Decreased microvessel density was observed in MCL3-treated group (×20), *P < 0.05 compared with control group

Click here to view


MCL3 decreased nuclear factor kappa B/Stat3 transcriptional activity

A dual-luciferase reporter assay was established to explore the effect of MCL3 on NF-κB and Stat3 transcription activity. The results showed that MCL3 inhibited NF-κB and Stat3 transcription activity [Figure 8]. The inhibition rate of NF-κB was 43.6% (P < 0.05) with 10.00 μmol/L MCL3, while the rate of Stat3 was 24.2% (P < 0.001) with 12.50 μmol/L MCL3, compared to the control group [Figure 8].
Figure 8: The effect of MCL3 on the nuclear factor kappa B/Stat3 signal pathway activity. (a) MCL3 inhibited nuclear factor kappa B transcriptional activity; (b) MCL3 inhibited Stat3 transcriptional activity. *P < 0.05, ***P < 0.001 compared with control group

Click here to view


MCL3 influenced the nuclear factor kappa B/interleukin-6/Stat3 signaling pathwayin vivo and in vitro

To elucidate the mechanism of MCL3, we analyzed the protein levels related to NF-κB/IL-6/Stat3 signaling pathway using western blotting. In vivo, 40.0 mg/kg MCL3 inhibited the phosphorylation of NF-κB, mediated by the suppression of phosphorylated IκBα, leading to decreased nuclear p-NF-κB [Figure 9]a, and inhibited the expression of IL-6 regulated by NF-κB.[14] Consequently, phosphorylation of Stat3 decreased,[16] resulting in the downregulation of Stat3 and NF-κB target genes, including hypoxia inducible factor (HIF), vascular endothelial growth factor (VEGF), matrix metalloproteinase ( MMP)-2, MMP-9, Bcl-2, Bcl-xL and Mcl-1[25],[26],[27],[28],[29] at 40.0 mg/kg MCL3 [Figure 9]b and [Figure 9]c.
Figure 9: The effect of MCL3 on the protein expression levels of nuclear factor kappa B/interleukin-6/Stat3 signaling pathway in vivo. (a) The expression of IκBα, and nuclear factor kappa B and the expression of p-nuclear factor kappa B in nuclear. (b) The expression of interleukin-6 and p-Stat3. (c) The expression of the Stat3/nuclear factor kappa B target genes. β-actin and Histone H3 were used as loading control

Click here to view


This study evaluated thein vitro protein expression of G422 cells after treatment with MCL3 for 72 h using the western blot assay. The results demonstrated that 10.00 μmol/L MCL3 decreased the phosphorylation of NF-κB and IκBα in G422 cells, and decreased nuclear p-NF-κB was observed, resulting in the low expression of IL-6 [Figure 10]a. Finally, decreased phosphorylation of Stat3 was observed in G422 cells, and in nuclear p-NF-κB [Figure 10]a and [Figure 10]b. Moreover, the target gene expression of Stat3 and NF-κB was reduced, including HIF, VEGF, MMP2, Bcl-2, and Mcl-1 [Figure 10]c.
Figure 10: The effect of MCL3 on the protein expression levels of nuclear factor kappa B/interleukin-6/Stat3 signaling pathway in vitro. (a) The expression of IκBα, nuclear factor kappa B, interleukin-6, and Stat3 in G422 cells treated with MCL3. (b) The expression of p-nuclear factor kappa B and p-Stat3 in nuclear treated with MCL3. (c) The expression of Stat3/nuclear factor kappa B target genes in G422 cells treated with MCL3. β-actin and Histone H3 were used as loading control

Click here to view



  Discussion Top


Radiotherapy combined with TMZ is the first-line treatment for GBM, but it could cause resistance and recurrence due to the heterogeneity.[30],[31] Furthermore, surgical resection was limited to the tumor location or the patient's poor physical status. Available therapeutic treatments and specific targets should be improved for GBM patients.[2]

TCM presents several advantages for cancer treatment, such as improving the anti-tumor effect of chemotherapy, reducing the chemotherapeutic drug resistance, and enhancing immune function. TCM combined with chemotherapy could enhance drug efficacy and decrease toxicity, and could thus serve as an effective adjuvant cancer therapy.[4]

Studies show that PTL inhibited the GBM growth via inhibiting NF-κB. ACT001, a derivative of PTL, modulated NF-κB to inhibit GBM growth, and ACT001 is currently in phase I clinical trials for advanced GBM treatment in China and Australia.[32] MCL3 was synthesized with a three-step reaction from the natural product PTL. In the present study, the effects of MCL3 on the proliferation, invasion, and angiogenesis GBM were detectedin vitro and in vivo. Results demonstrated that MCL3 inhibited GBM cell (G422, U-87 MG, U251 and Hs683 cell lines) proliferation in vitro, and G422 GBM growth in vivo. In addition, MCL3 suppressed the invasion of G422 cells, and suppressed tube formation in EA. hy926 cells.

Previous studies have shown that activated NF-κB increases the expression of IL-6, and IL-6 could lead to the activation of Stat3.[13],[33]In vitro and in vivo results have concurred that MCL3 inhibits the phosphorylation of nuclear mediated NF-κB via the suppression of phosphorylated IκB,[15] and decreases the expression of IL-6 regulated by NF-κB.[34] Consequently, the phosphorylation of IL-6-induced Stat3 was found to be reduced.[35] MCL3 inhibited G422 tumor growth through the inhibition of the NF-κB/IL-6/Stat3 signaling pathway.

NF-κB and Stat3 have been reported to be the significant transcription factors regulating the downstream genes associated with cell proliferation, apoptosis, invasion, and angiogenesis in cancer.[36],[37] A dual-luciferase reporter assay suggested that MCL3 inhibited the transcription activities of NF-κB and Stat3. Previous studies have suggested that NF-κB and Stat3 determine the expression of HIF-1α and VEGF, which play essential roles in vessel formation.[25],[29],[38] Western blotting performed in the current study supported this evidence as MCL3 decreased the expression of p-NF-κB and p-Stat3, then reduced the levels of downstream proteins HIF-1α and VEGF[39]in vivo and in vitro, which were associated with angiogenesis.

Cancer cell invasion and metastasis could accelerate based on critical compounds for invasion, such as MMP2, MMP9.[27] Other studies suggested that NF-κB activation regulated the expression of MMP9,[26] while Stat3 enhanced the expression of MMP2, which is linked to metastatic activity.[34] The study is in agreement with these findings, as the inhibition of p-NF-κB and p-Stat3 of MCL3 decreased the expression of its downstream proteins MMP9 and MMP2,in vitro and in vivo. Moreover, the inhibition of p-NF-κB and p-Stat3 decreased the levels of downstream proteins Bcl-2, Bcl-xL and Mcl-1, which were associated with cell apoptosis.[39],[40],[41],[42] The results showed that MCL3-induced apoptosis, suppressed tumor proliferation, invasion, and angiogenesis in G422 GBM, mediated by the NF-κB/IL-6/Stat3 signaling pathway. Furthermore, the IHC results also confirmed that tumor proliferation and angiogenesis were suppressed with the treatment of MCL3 in G422 xenograft tumor model.[39]


  Conclusion Top


The results demonstrated that MCL3 could induce apoptosis, inhibit G422 GBM growth, metastasis, and angiogenesis via the suppression of the NF-κB/IL-6/Stat3 signaling pathway. On the basis of this data, we suggest that MCL3 may be an effective treatment component for GBM.

Financial support and sponsorship

This work was supported by the Chinese Academy of Medical Sciences (CAMS) Initiation fund for Medical Science (2016-I2M-1-008) and the Drug Innovation Major Project (2018ZX09711-001-005).

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: Updated approaches from recent biological insights. Ann Oncol 2017;28:1457-72.  Back to cited text no. 1
    
2.
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013;310:1842-50.  Back to cited text no. 2
    
3.
Braun K, Ahluwalia MS. Treatment of glioblastoma in older adults. Curr Oncol Rep 2017;19:81.  Back to cited text no. 3
    
4.
Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends 2015;9:16-34.  Back to cited text no. 4
    
5.
Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-503.  Back to cited text no. 5
    
6.
Xue JX, Zhu ZY, Bian WH, Yao C. The traditional Chinese medicine Kangai injection as an adjuvant method in combination with chemotherapy for the treatment of breast cancer in Chinese patients: A meta-analysis. Evid Based Complement Alternat Med 2018;2018:6305645.  Back to cited text no. 6
    
7.
Jafari N, Nazeri S, Enferadi ST. Parthenolide reduces metastasis by inhibition of vimentin expression and induces apoptosis by suppression elongation factor α-1 expression. Phytomedicine 2018;41:67-73.  Back to cited text no. 7
    
8.
Sun Y, St. Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA, et al. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 2007;6:2477-86.  Back to cited text no. 8
    
9.
Lu C, Wang W, Jia Y, Liu X, Tong Z, Li B. Inhibition of AMPK/autophagy potentiates parthenolide-induced apoptosis in human breast cancer cells. J Cell Biochem 2014;115:1458-66.  Back to cited text no. 9
    
10.
Oka D, Nishimura K, Shiba M, Nakai Y, Arai Y, Nakayama M, et al. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int J Cancer 2007;120:2576-81.  Back to cited text no. 10
    
11.
Talib WH, Al Kury LT. Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 – Dependent apoptosis and inhibiting VEGF expression. Biomed Pharmacother 2018;107:1488-95.  Back to cited text no. 11
    
12.
Kim SL, Lee ST, Trang KT, Kim SH, Kim IH, Lee SO, et al. Parthenolide exerts inhibitory effects on angiogenesis through the down regulation of VEGF/VEGFRs in colorectal cancer. Int J Mol Med 2014;33:1261-7.  Back to cited text no. 12
    
13.
Nakabayashi H, Shimizu K. Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cellsin vitro and in vivo. BMC Cancer 2012;12:453.  Back to cited text no. 13
    
14.
Liang S, Chen Z, Jiang G, Zhou Y, Liu Q, Su Q, et al. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals. Cancer Lett 2017;386:12-23.  Back to cited text no. 14
    
15.
Napetschnig J, Wu H. Molecular basis of NF-κB signaling. Annu Rev Biophys 2013;42:443-68.  Back to cited text no. 15
    
16.
Fang ZZ, Tanaka N, Lu D, Jiang CT, Zhang WH, Zhang C, et al. Role of the lipid-regulated NF-κB/IL-6/STAT3 axis in alpha-naphthyl isothiocyanate-induced liver injury. Arch Toxicol 2017;91:2235-44.  Back to cited text no. 16
    
17.
García-Piñeres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, et al. Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 2001;276:39713-20.  Back to cited text no. 17
    
18.
Zhai JD, Li D, Long J, Zhang HL, Lin JP, Qiu CJ, et al. Biomimetic semisynthesis of arglabin from parthenolide. J Org Chem 2012;77:7103-7.  Back to cited text no. 18
    
19.
Li Y, Tang K, Zhang L, Li C, Niu F, Zhou W, et al. The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth. Cancer Lett 2015;356:392-403.  Back to cited text no. 19
    
20.
Chaloob MK, Ali HH, Qasim BJ, Mohammed AS. Immunohistochemical expression of Ki-67, PCNA and CD34 in astrocytomas: A clinicopathological study. Oman Med J 2012;27:368-74.  Back to cited text no. 20
    
21.
Ilamathi M, Prabu PC, Ayyappa KA, Sivaramakrishnan V. Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling. Biomed Pharmacother 2016;82:72-9.  Back to cited text no. 21
    
22.
Godoy A, Salazar K, Figueroa C, Smith GJ, de Los Angeles Garcia M, Nualart FJ. Nutritional channels in breast cancer. J Cell Mol Med 2009;13:3973-84.  Back to cited text no. 22
    
23.
Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010;70:1053-62.  Back to cited text no. 23
    
24.
Medri L, Nanni O, Volpi A, Scarpi E, Dubini A, Riccobon A, et al. Tumor microvessel density and prognosis in node-negative breast cancer. Int J Cancer 2000;89:74-80.  Back to cited text no. 24
    
25.
Li Y, Sui H, Jiang C, Li S, Han Y, Huang P, et al. Dihydroartemisinin increases the sensitivity of photodynamic therapy via NF-κB/HIF-1α/VEGF pathway in esophageal cancer cellin vitro and in vivo. Cell Physiol Biochem 2018;48:2035-45.  Back to cited text no. 25
    
26.
Luo KW, Wei Chen, Lung WY, Wei XY, Cheng BH, Cai ZM, et al. EGCG inhibited bladder cancer SW780 cell proliferation and migration bothin vitro andin vivo via down-regulation of NF-κB and MMP-9. J Nutr Biochem 2017;41:56-64.  Back to cited text no. 26
    
27.
Park JH, Cho YY, Yoon SW, Park B. Suppression of MMP-9 and FAK expression by pomolic acid via blocking of NF-κB/ERK/mTOR signaling pathways in growth factor-stimulated human breast cancer cells. Int J Oncol 2016;49:1230-40.  Back to cited text no. 27
    
28.
Zaanan A, Okamoto K, Kawakami H, Khazaie K, Huang S, Sinicrope FA. The mutant KRAS gene up-regulates BCL-XL protein via STAT3 to confer apoptosis resistance that is reversed by BIM protein induction and BCL-XL antagonism. J Biol Chem 2015;290:23838-49.  Back to cited text no. 28
    
29.
Aghazadeh S, Yazdanparast R. Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN. Biochim Biophys Acta Gen Subj 2017;1861:1970-80.  Back to cited text no. 29
    
30.
Osuka S, Van Meir EG. Overcoming therapeutic resistance in glioblastoma: The way forward. J Clin Invest 2017;127:415-26.  Back to cited text no. 30
    
31.
Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 2014;232:165-77.  Back to cited text no. 31
    
32.
Li Q, Sun Y, Liu B, Li J, Hao X, Ge W, et al. ACT001 modulates the NF-κB/MnSOD/ROS axis by targeting IKKβ to inhibit glioblastoma cell growth. J Mol Med (Berl) 2020;98:263-77.  Back to cited text no. 32
    
33.
Sohma I, Fujiwara Y, Sugita Y, Yoshioka A, Shirakawa M, Moon JH, et al. Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 2011;8:39-47.  Back to cited text no. 33
    
34.
Zhu Y, Zhang X, Wang L, Ji Z, Xie M, Zhou X, et al. Loss of SH3GL2 promotes the migration and invasion behaviours of glioblastoma cells through activating the STAT3/MMP2 signalling. J Cell Mol Med 2017;21:2685-94.  Back to cited text no. 34
    
35.
Latourte A, Cherifi C, Maillet J, Ea HK, Bouaziz W, Funck-Brentano T, et al. Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. Ann Rheum Dis 2017;76:748-55.  Back to cited text no. 35
    
36.
Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res 2014;2:823-30.  Back to cited text no. 36
    
37.
Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer 2016;138:2570-8.  Back to cited text no. 37
    
38.
Yang M, Wang L, Wang X, Wang X, Yang Z, Li J. IL-6 promotes FSH-induced VEGF expression through JAK/STAT3 signaling pathway in bovine granulosa cells. Cell Physiol Biochem 2017;44:293-302.  Back to cited text no. 38
    
39.
Ingaleshwar PS, Pandit S, Desai D, Redder CP, Shetty AS, Mithun KM. Immunohistochemical analysis of angiogenesis by CD34 and mast cells by toluidine blue in different grades of oral squamous cell carcinoma. J Oral Maxillofac Pathol 2016;20:467-73.  Back to cited text no. 39
[PUBMED]  [Full text]  
40.
Li Y, Wang Y, Li L, Kong R, Pan S, Ji L, et al. Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway bothin vitro and in vivo. Tumour Biol 2016;37:7345-55.  Back to cited text no. 40
    
41.
Zhuang Z, Sun XJ, Zhang X, Liu HD, You WC, Ma CY, et al. Nuclear factor-κB/Bcl-XL pathway is involved in the protective effect of hydrogen-rich saline on the brain following experimental subarachnoid hemorrhage in rabbits. J Neurosci Res 2013;91:1599-608.  Back to cited text no. 41
    
42.
Yu RX, Yu RT, Liu Z. Inhibition of two gastric cancer cell lines induced by fucoxanthin involves downregulation of Mcl-1 and STAT3. Hum Cell 2018;31:50-63.  Back to cited text no. 42
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9], [Figure 10]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Introduction
Materials and Me...
Results
Discussion
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed25    
    Printed0    
    Emailed0    
    PDF Downloaded5    
    Comments [Add]    

Recommend this journal